Why did JuneYao Health Stock fall?

Affected by repeated outbreaks and prevention and control efforts, the willingness and ability to consume have been significantly impacted, and the pace of distribution partners has also slowed down. At the same time, the core area of the company was affected by the flood in the peak sales season, which affected a large area and affected it for a long time, causing serious interference to the company's operation. Affected by the above negative factors, the performance in 2020 will decline.

1. Juneyao Group has entered the dairy products and milk-containing beverages industry since the 1990s, and has gradually become a well-known brand in this industry. It is one of the earliest enterprises in China to develop and produce long-term sterilized milk in plastic bottles. When it comes to Junyao brand, we must avoid Wang Junyao, a bold entrepreneur. Junyao Group is named after its founder Wang Junyao. In the early 1980s, Wang Junyao, Wang Junjin and Wang Junhao were born in an ordinary fisherman's family in Cangnan County, Wenzhou. In the early days of reform and opening up, big brother Wang Junyao and his brothers started a small business together. Starting with the simplest way to make money, they are constantly looking for opportunities every day. Wenzhou people's spirit of hard work, daring to take risks and seizing opportunities is well reflected in the Wangs.

2. On August 18, JuneYao Health (605388), known as "the first lactic acid bacteria stock", officially landed on the main board of Shanghai Stock Exchange, and JuneYao Health became the fourth listed enterprise of JuneYao Group. 1998, the predecessor of Junyao Health, Junyao Group Dairy Co., Ltd. was established, which inherited the dairy products and milk-containing beverages business of the Group. On 20 1 1 year, Junyao launched a series of new products of "Taste Power" and strategically entered the room temperature lactic acid bacteria beverage market, with rapid growth in performance.

3. As the first annual performance answer sheet after landing in A-shares, Junyao Health's performance in 2020 can be described as "morbid", with income and profit declining, and the production and sales of normal-temperature lactic acid bacteria also shrinking in double digits. Recently, Junyao Health released its 2020 annual report, achieving revenue of about 852 million yuan, down 365,438+0.62% year-on-year; The net profit attributable to shareholders of listed companies was about 2,654,380,400 yuan, down 27.6% from 295 million yuan in the same period last year, and the revenue and net profit showed a double downward trend.